[A24-14] Patiromer (hyperkalaemia in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2024
Project no.:
A24-14
Commission:
Commission awarded on 01.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Indication:
Children and adolescents aged 12 and older with hyperkalaemia
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the decides of the G-BA website.
DOI:
https://doi.org/10.60584/A24-14_en
| Project no. | Title | Status |
|---|---|---|
| A18-21 | Patiromer (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |